Clinical Trial

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-14; most recent amendment 2025-12-05.
Status change: Not Yet Recruiting → Recruiting 2025-12-05
Trial Details
NCT Number NCT07235527
Lead Sponsor Saglik Bilimleri Universitesi
Conditions Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration, Anti Vascular Endothelial Growth Factor
Enrollment 54 participants
Start Date 2025-11-20
Primary Completion 2026-06-20 (estimated)
Study Completion 2026-08-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-08